Table 3 Patient demographics and clinical characteristics in the pool of saxagliptin add-on to metformin studies
Characteristic, n (%) | All SAXA | Control |
|---|---|---|
(n = 2981) | (n = 2190) | |
Age, y | Â | Â |
  <65 | 2397 (80.4) | 1733 (79.1) |
  ≥65 | 584 (19.6) | 457 (20.9) |
  ≥75 | 86 (2.9) | 62 (2.8) |
Women | 1533 (51.4) | 1070 (48.9) |
Race | Â | Â |
  White | 2031 (68.1) | 1426 (65.1) |
  Asian | 549 (18.4) | 469 (21.4) |
  Black | 109 (3.7) | 58 (2.6) |
  Other | 292 (9.8) | 237 (10.8) |
BMI, kg/m2 | Â | Â |
  <30 | 1438 (48.2) | 1114 (50.9) |
  ≥30 | 1541 (51.7) | 1074 (49.0) |
  Not reported | 2 (<0.1) | 2 (<0.1) |
Duration of T2DM, y | Â | Â |
  ≤1.5 | 828 (27.8) | 504 (23.0) |
  ≤3 | 1198 (40.2) | 833 (38.0) |
  >3– < 5 | 475 (15.9) | 386 (17.6) |
  ≥5 | 1308 (43.9) | 971 (44.3) |
  ≥10 | 489 (16.4) | 391 (17.9) |
Creatinine clearance, mL/min | Â | Â |
  30– < 50 | 28 (0.9) | 14 (0.6) |
  50–80 | 493 (16.5) | 405 (18.5) |
  >80 | 2457 (82.4) | 1768 (80.7) |
  Not reported | 3 (0.1) | 3 (0.1) |